| Literature DB >> 29737506 |
Yu Liu1, Deyu Zhou1, Jiabin Feng1, Zhou Liu1, Yue Hu1, Chang Liu2, Xiaohong Kong3.
Abstract
Despite the success of combined antiretroviral therapy in recent years, the prevalence of human immunodeficiency virus (HIV)-associated neurocognitive disorders in people living with HIV-1 is increasing, significantly reducing the health-related quality of their lives. Although neurons cannot be infected by HIV-1, shed viral proteins such as transactivator of transcription (Tat) can cause dendritic damage. However, the detailed molecular mechanism of Tat-induced neuronal impairment remains unknown. In this study, we first showed that recombinant Tat (1-72 aa) induced neurotoxicity in primary cultured mouse neurons. Second, exposure to Tat1-72 was shown to reduce the length and number of dendrites in cultured neurons. Third, Tat1-72 (0-6 h) modulates protein phosphatase 1 (PP1) expression and enhances its activity by decreasing the phosphorylation level of PP1 at Thr320. Finally, Tat1-72 (24 h) downregulates CREB activity and CREB-mediated gene (BDNF, c-fos, Egr-1) expression. Together, these findings suggest that Tat1-72 might impair cognitive function by regulating the activity of PP1 and the CREB/BDNF pathway.Entities:
Keywords: CREB/BDNF; Dendrite impairment; HIV-associated neurocognitive disorders (HAND); Protein phosphatase 1 (PP1); Recombinant tat
Mesh:
Substances:
Year: 2018 PMID: 29737506 PMCID: PMC6178559 DOI: 10.1007/s12250-018-0031-4
Source DB: PubMed Journal: Virol Sin ISSN: 1995-820X Impact factor: 4.327